Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic cancer (specifically pancreatic ductal adenocarcinoma) that has spread to other parts of the body, confirmed by a laboratory test on a tissue or cell sample.
• People aged 18 or older.
• People who are generally able to carry out daily activities with no or minimal limitations (as rated by a standard medical scale called ECOG, with a score of 0 or 1).
• People whose blood test results show healthy enough levels of white blood cells, platelets, liver enzymes, kidney function, and protein in the blood — the trial site will check these specific values.
• People who have at least one area of cancer that can be measured on a scan, according to standard medical guidelines.
• People who either have a stored tumour tissue sample available, or who have a tumour that can be safely biopsied before treatment begins.
• People who are willing and able to self-administer the study drug (a caregiver may also assist with this).
• People who are willing to receive certain vaccines (against meningococcal and pneumococcal bacteria) if they have not already had them.
• People who are willing to use reliable contraception during the study and for a period after the last treatment (6 months for women who could become pregnant; 3 months for men), and who agree not to donate eggs or sperm during those timeframes.
• People who are willing to sign a written consent form after being informed about the investigational nature of the study.

Who may not be able to join:

• People who have previously received chemotherapy for pancreatic cancer — though gemcitabine-based treatment given before or after surgery may be acceptable if the last dose or surgery happened at least 6 months before the cancer was confirmed to have spread (confirm with trial site).
• People who still have side effects from a previous treatment rated above a mild level (with the exception of hair loss and fatigue).
• People with severe fluid build-up in the abdomen or around the lungs that requires draining weekly or more often, or that requires a permanent drainage tube.
• People with a blockage in the bowel or stomach outlet that is currently untreated — though people who had such a blockage within the past 6 weeks and whose symptoms are now well managed may still be considered (confirm with trial site).
• People with brain metastases (cancer that has spread to the brain) that have not been treated.
• People with serious uncontrolled illnesses, such as an active infection, heart failure, unstable chest pain, irregular heart rhythms, or mental health or social circumstances that would make it difficult to follow the study requirements.
• People who have had a serious blood clot in an artery or vein (such as a heart attack, stroke, deep vein thrombosis, or pulmonary embolism) within the 6 months before starting the study treatment.
• People who are pregnant or breastfeeding.
• People who are unwilling or unable to follow the study's requirements.
• People whom the trial doctor considers unsuitable for the study drug for any other reason.

Important: Always verify eligibility with the trial site directly before applying.